INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,055,000 | +68.5% | 8,512 | +8.2% | 0.05% | +48.6% |
| Q2 2019 | $626,000 | -35.1% | 7,864 | -8.7% | 0.04% | -39.7% |
| Q1 2019 | $964,000 | -35.1% | 8,617 | -41.6% | 0.06% | -39.6% |
| Q4 2018 | $1,486,000 | +91.5% | 14,745 | +140.0% | 0.10% | +174.3% |
| Q3 2018 | $776,000 | -51.9% | 6,145 | -76.6% | 0.04% | -46.2% |
| Q1 2018 | $1,614,000 | -57.5% | 26,245 | -59.7% | 0.06% | -61.3% |
| Q4 2017 | $3,799,000 | +438.1% | 65,045 | +900.7% | 0.17% | +300.0% |
| Q4 2016 | $706,000 | -26.9% | 6,500 | +0.5% | 0.04% | -8.7% |
| Q4 2015 | $966,000 | -73.4% | 6,469 | -72.3% | 0.05% | -66.2% |
| Q4 2014 | $3,637,000 | -29.0% | 23,317 | +7.8% | 0.14% | -42.6% |
| Q3 2014 | $5,121,000 | +220.5% | 21,636 | +220.2% | 0.24% | +185.5% |
| Q2 2014 | $1,598,000 | – | 6,756 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |